86 citations
,
November 2020 in “Annals of Oncology” These guidelines discuss prevention and management strategies for dermatological toxicities but report no new clinical results; they include expert recommendations for conditions like acneiform rash and hand-foot syndrome.
24 citations
,
August 2020 in “JAMA dermatology” In this study, researchers observed a dose-dependent occurrence of persistent radiation-induced alopecia in patients with primary CNS tumors or head and neck sarcomas, noting distinctive patterns and features, and suggesting potential benefits of topical minoxidil and procedural interventions for treatment.
17 citations
,
June 2020 in “Anais brasileiros de dermatologia/Anais Brasileiros de Dermatologia” This paper provides an overview of scalp cooling as an effective and safe intervention for preventing chemotherapy-induced alopecia, addressing its impact on cancer patients and survivors.
29 citations
,
December 2019 in “Stem Cells Translational Medicine” This review discusses the current challenges and strategies in hair follicle bioengineering for treating hair loss and reports no new clinical results; it highlights ongoing hurdles and future directions for developing functional hair regeneration therapies.
43 citations
,
March 2019 in “JAMA Dermatology” This study found that persistent chemotherapy-induced alopecia is often more severe and diffuse than alopecia from endocrine therapy, with both conditions negatively impacting patients' emotional wellbeing, and moderate to significant improvement was observed with dermatologic therapy.
22 citations
,
November 2018 in “Breast Cancer Research and Treatment” In this review, researchers found no evidence of interactions between 5α-reductase inhibitors or spironolactone and endocrine therapies for breast cancer, with no consistent changes in estrogen levels or increased breast cancer risk associated with spironolactone usage.
179 citations
,
October 2018 in “American Journal of Clinical Dermatology” This review outlines various dermatologic adverse events associated with targeted therapies and immunotherapies, emphasizing the need for collaboration between dermatologists and oncologists to manage these effects effectively; it reports no new clinical findings.
59 citations
,
August 2018 in “The oncologist” This study found that permanent chemotherapy-induced alopecia was relatively common three years after treatment among breast cancer patients receiving adjuvant chemotherapy, particularly those on taxane-based regimens.
32 citations
,
May 2018 in “Journal of the American Academy of Dermatology” This review describes how cutaneous toxicity from kinase inhibitors, immune checkpoint inhibitors, and chemotherapeutics could potentially serve as a biomarker for anticancer treatment efficacy, but highlights the need for more extensive research to confirm this association.
53 citations
,
April 2018 in “Journal of The American Academy of Dermatology” This article reviews therapy-related hair disorders in oncology patients, detailing underlying mechanisms and potential management strategies, but reports no new clinical findings.
67 citations
,
April 2018 in “JAMA Dermatology” This study found that endocrine therapy for breast cancer is associated with a pattern of hair loss similar to androgenetic alopecia, negatively impacting quality of life despite mild severity.
38 citations
,
September 2017 in “Oncologist” This source reports that scalp cooling is currently the only safe and FDA-cleared method to potentially reduce chemotherapy-induced hair loss, with about a 50% chance of maintaining sufficient hair to avoid needing a wig.
28 citations
,
July 2017 in “Expert Review of Anticancer Therapy” This study found that CDK4/6 inhibitors in hormone-positive metastatic breast cancer were linked to increased risks of fatigue, alopecia, and stomatitis compared to placebo.
16 citations
,
March 2017 in “Bone Marrow Transplantation” In this study, permanent alopecia after haematopoietic stem cell transplantation was found in 16% of patients and was significantly associated with conditioning regimens involving busulphan.
38 citations
,
March 2017 in “Expert Opinion on Investigational Drugs” This review examines the potential of bimatoprost for treating various types of eyelash and eyebrow hypotrichosis, discussing its pharmacological properties but providing no new clinical results.
79 citations
,
January 2017 in “Dermatology practical & conceptual” This article addresses the need to screen for nutrient deficiencies in patients with hair loss but reports no new findings, noting that supplementation without deficiency may not be beneficial and could pose risks.
87 citations
,
December 2016 in “British journal of dermatology/British journal of dermatology, Supplement” This study describes and characterizes four cases of alopecia areata induced by immune checkpoint inhibitor therapy in cancer patients, highlighting the importance of recognizing and managing these hair-related adverse events.
17 citations
,
June 2016 in “Croatian Medical Journal” In this study, vitiligo and alopecia areata were more common among patients with chronic graft-vs-host disease than previously reported, linked to higher NIH skin scores and greater immunosuppressive treatment.
44 citations
,
September 2015 in “Annals of Oncology” This study reported that targeted anticancer therapies are associated with an increased risk of alopecia compared to placebo, although the risk was lower compared to chemotherapy.
26 citations
,
January 2014 in “Annals of Dermatology” This report describes a 33-year-old woman who developed alopecia neoplastica due to gastric adenocarcinoma, highlighting the role of tumor invasion in hair follicle atrophy.
34 citations
,
November 2013 in “Breast Cancer Research and Treatment” This study found that female breast cancer survivors using aromatase inhibitors were observed to have a higher likelihood of experiencing hair loss and thinning compared to those not treated with these drugs.
48 citations
,
September 2013 in “Oncologist” This study reported that alopecia is a common but often underreported side effect of endocrine-based cancer therapies, with tamoxifen showing the highest incidence of hair loss among analyzed treatments.
32 citations
,
September 2013 in “Breast cancer research” This study identified a specific SNP in the CACNB4 gene associated with a higher risk of chemotherapy-induced alopecia in breast cancer patients, which may help develop interventions to improve their quality of life.
52 citations
,
May 2013 in “Supportive Care in Cancer” Scalp cooling significantly reduces hair loss in chemotherapy patients.
218 citations
,
January 2013 in “The Lancet Oncology” This review discusses the pathobiology of chemotherapy-induced alopecia and highlights challenges in managing it, reporting no new clinical results and emphasizing the need for well-designed preclinical models to develop effective treatments.
68 citations
,
May 2012 in “Annals of Oncology” This study reports that permanent and severe alopecia is a newly identified complication of the FEC 100–docetaxel regimen used for adjuvant breast cancer treatment.
42 citations
,
April 2012 in “Seminars in Oncology” This review discusses the skin side effects associated with targeted cancer therapies and reports no new clinical results; it emphasizes the need for empirical management based on expert opinion.
31 citations
,
June 2011 in “Journal of the neurological sciences” In this case report, a patient with thymoma was observed to have four co-occurring paraneoplastic autoimmune disorders that improved after thymectomy, suggesting a possible link between thymoma and these conditions.
67 citations
,
May 2010 in “Journal of The American Academy of Dermatology” This article discusses a unique case of permanent chemotherapy-induced alopecia in a patient receiving chemotherapy for breast cancer, characterized by a distinctive histologic finding and excludes bone marrow transplantation, but reports no new clinical results.
61 citations
,
April 2009 in “British journal of dermatology/British journal of dermatology, Supplement” This study found that irreversible and severe alopecia can occur following docetaxel or paclitaxel chemotherapy in breast cancer patients.
28 citations
,
January 2007 in “Dermatology” This article discusses the presentation of chemotherapy-induced anagen effluvium as either diffuse or patterned hair loss and reports no new clinical findings.
120 citations
,
October 2004 in “International journal of radiation oncology, biology, physics” In this study, the researchers established a dose–response relationship between the hair follicle dose during cranial irradiation and the development of permanent alopecia, with other factors showing limited correlation.
19 citations
,
June 2001 in “Annals of Internal Medicine” This case report describes total alopecia in a 53-year-old woman after 13 months of tamoxifen treatment for breast cancer, with normal hair distribution maintained elsewhere.
127 citations
,
July 1996 in “Journal of The American Academy of Dermatology” This study found that in women undergoing chemotherapy after breast surgery, topical minoxidil significantly shortened the duration of hair loss compared to a placebo without significant side effects.
